research P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib was more effective than methotrexate for treating alopecia areata.
Search
for
Sort by
Research
810-840 / 1000+ results
research Upadacitinib for the treatment of alopecia areata – A case report
Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
research Baricitinib (Olumiant)
Olumiant should be covered for severe alopecia areata if certain conditions are met.
research Platelet-rich plasma in the treatment of alopecia areata: A retrospective evaluation of 17 patients
PRP treatment may help with alopecia areata, especially in newer cases.
research Frontal fibrosing alopecia in males: A systematic review
Frontal fibrosing alopecia significantly affects men, often causing hair loss in eyebrows, beard, and sideburns.
research Evaluating the Causal Relationship Between Human Blood Metabolites and the Susceptibility to Alopecia Areata
Blood metabolites significantly influence alopecia areata risk.
research Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
research A perspective on predictive markers of alopecia
Certain immune molecules and stress affect hair loss, and while genes play a role, more research is needed to fully understand and treat it.
research Systemic Tofacitinib in Alopecia Areata: A Single Center Retrospective Descriptive Cohort Study
Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
research Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
Alopecia areata patients have higher risks of infections, lymphoma, heart issues, and death.
research Efficacy and safety of tofacitinib in patients with total and universal alopecia- A retrospective evaluation of 69 patients
Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
research Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real‐World Cohort Study
Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
research BH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists
Dermatologists vary widely in testing practices for alopecia areata, often exceeding guideline recommendations.
research Growth Factors and Microneedling in Alopecia Areata: A Narrative Review
Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.
research A Novel Topical Compound Gel Loading Minoxidil and Tofacitinib for Treatment of Alopecia Areata: Formulation, Characterization, and In Vitro/In Vivo Evaluation
The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
research Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
Deucravacitinib helped a man regrow hair and improve psoriasis.
research The therapeutic, diagnostic, and prognostic values of extracellular vesicles (exosomes) in dermatology: A systematic review
Extracellular vesicles show potential in dermatology, but more research is needed for validation.
research Is Intralesional Methotrexate an Effective Alternative to Intralesional Triamcinolone in Alopecia Areata? Findings From a Randomized Controlled Trial
Triamcinolone is more effective than methotrexate for treating localized alopecia areata.
research Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
research Smart Biomaterials and Dressings for the Treatment of Chronic Inflammatory Skin Diseases
Smart biomaterials and dressings show promise in treating chronic skin diseases by improving drug delivery and minimizing side effects.
research Analyse trichoskopischer Bilder mit tiefen neuronalen Netzen zur Diagnose und Aktivitätsbewertung von Alopecia areata – eine retrospektive Studie
Deep-learning models can effectively diagnose and assess Alopecia areata using scalp images.
research Overcoming Curcumin's Limitations: Synthetic Derivatives in Diabetes and Cancer Management
Synthetic curcumin derivatives improve treatment for diabetes and cancer.
research Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles
Foam corticosteroid covers as well as traditional forms.
research Differential cold stress intensities drive unique morphological and transcriptomic changes in Zea mays root hairs
Maize root hairs adapt differently to mild and severe cold, with mild stress allowing some growth and severe stress stopping growth to focus on defense.
research Epidermal-Derived Hedgehog Signaling Drives Mesenchymal Proliferation during Digit Tip Regeneration
Epidermal signaling helps regenerate fingertip tissue.
research Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research Reddit Analysis Reveals Common Questions of Patients with Alopecia Areata about JAK Inhibitors for Hair Loss.
research Alopecia Areata
Alopecia areata causes hair loss and needs personalized care to manage its emotional and social effects.
research Adjunctive Dupilumab Therapy in a Partial Responder to Baricitinib for Alopecia Areata
Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.